A Bayesian weighted quasi-likelihood design for phase I/II clinical trial with repeated dose administration in preterm newborns

被引：0
|
作者：
Ursino, Moreno [1 ]
Yuan, Ying [2 ]
Alberti, Corinne [3 ]
Comets, Emmanuelle [4 ,5 ]
Friede, Tim [6 ]
Lents, Frederike [7 ]
Stallard, Nigel [8 ]
Zohar, Sarah [1 ]
机构：
[1] INSERM, UMRS1138, Team22, Paris, France
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] INSERM, UMR 1123, Paris, France
[4] INSERM, CIC 1414, Paris, France
[5] INSERM IAME, UMR 1137, Paris, France
[6] Univ Med Ctr Gottingen, Gottingen, Germany
[7] Fed Inst Drugs & Med Devices, Bonn, Germany
[8] Univ Warwick, Warwick Med Sch, Warwick, England
来源：
TRIALS | 2017年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
P343
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A parallel phase I/II clinical trial design for combination therapies
    Huang, Xuelin
    Biswas, Swati
    Oki, Yasuhiro
    Issa, Jean-Pierre
    Berry, Donald A.
    BIOMETRICS, 2007, 63 (02) : 429 - 436
  • [22] Modified isotonic regression based phase I/II clinical trial design identifying optimal biological dose
    Qiu, Yingjie
    Zhao, Yi
    Liu, Hao
    Cao, Sha
    Zhang, Chi
    Zang, Yong
    CONTEMPORARY CLINICAL TRIALS, 2023, 127
  • [23] A Bayesian seamless phase I-II trial design with two stages for cancer clinical trials with drug combinations
    Jimenez, Jose L.
    Kim, Sungjin
    Tighiouart, Mourad
    BIOMETRICAL JOURNAL, 2020, 62 (05) : 1300 - 1314
  • [24] Bayesian dose-finding phase I trial design incorporating historical data from a preceding trial
    Takeda, Kentaro
    Morita, Satoshi
    PHARMACEUTICAL STATISTICS, 2018, 17 (04) : 372 - 382
  • [25] A bayesian approach for dose-escalation in a phase I clinical trial incorporating pharmacodynamic endpoints
    Whitehead, John
    Zhou, Yinghui
    Hampson, Lisa
    Ledent, Edouard
    Pereira, Alvaro
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2007, 17 (06) : 1117 - 1129
  • [26] A Bayesian dose-finding procedure applied to a seamless phase I/II trial in rheumatoid arthritis
    Anne Whitehead
    Helene Thygesen
    Vladimir Dragalin
    John Whitehead
    Trials, 12 (Suppl 1)
  • [27] Adaptive Cohort Size Determination Method for Bayesian Optimal Interval Phase I/II Design to Shorten Clinical Trial Duration
    Kojima, Masahiro
    JCO PRECISION ONCOLOGY, 2023, 7
  • [28] A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation
    Jin Xu
    Dapeng Zhang
    Rongji Mu
    BMC Medical Research Methodology, 22
  • [29] A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation
    Xu, Jin
    Zhang, Dapeng
    Mu, Rongji
    BMC MEDICAL RESEARCH METHODOLOGY, 2022, 22 (01)
  • [30] Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials
    Takahashi, Ami
    Suzuki, Taiji
    INTERNATIONAL JOURNAL OF BIOSTATISTICS, 2022, 18 (01): : 39 - 56
12345